-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$5.6734.68% Upside
SAB Biotherapeutics, Inc. Frequently Asked Questions
-
What analysts cover SAB Biotherapeutics, Inc.?
SAB Biotherapeutics, Inc. has been rated by research analysts at Loop Capital Markets, H.C. Wainwright, Chardan Capital in the past 90 days.